Skip to content

Risk assessment of COVID-19 vaccine in patients with epilepsy: a multicenter prospective observational study

Risk assessment of COVID-19 vaccine in patients with epilepsy: a multicenter prospective observational study

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100048134
Enrollment
Unknown
Registered
2021-07-04
Start date
2021-07-05
Completion date
Unknown
Last updated
2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Case series:No

Sponsors

Qilu Hospital, Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with epilepsy according to the criteria proposed by the International Anti-Epilepsy Union in 2017; 2. Aged 18 to 65 years; 3. Patients did not have seizures 6 months before vaccination 4. Patients and their family members gave informed consent to participate in this study voluntarily.

Exclusion criteria

Exclusion criteria: 1. Have a clear history of vaccine-induced seizures or exacerbation of seizures; 2. Four weeks before inoculation, the frequency of seizures in basal line stage was frequent, or there was epileptic status; 3. lactating women or pregnant women; 4. Have a history of other medical diseases and mental illness; 5. Severe liver and kidney dysfunction or severe infection; 6. known history of alcohol or drug addiction or abuse; 7. People with allergy; 8. Patients and their families refused to participate in this study.

Design outcomes

Primary

MeasureTime frame
number of seizures after vaccination;

Secondary

MeasureTime frame
Adverse reactions;Result of electroencephalogram;

Countries

China

Contacts

Public ContactLiu Xuewu

Qilu Hospital, Shandong University

snlxw1966@163.com+86 18560085520

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026